Nuwellis, Inc. Announces Second Quarter 2022 Financial Results
- Generated
$2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022, - Enrolled first patient in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy, and
- Decreased operating expenses 14% compared to the second quarter of 2021 to minimize cash utilization while continuing to fund key strategic initiatives.
“I am very happy with our strong sequential performance in the quarter and remain encouraged by our considerable progress in executing our strategy to make the Aquadex System the standard of care for diuretic resistant patients needing fluid balance in the ICU or because of suffering from heart failure,” said
Second Quarter 2022 Financial Results
Total revenue for the second quarter of 2022 was
Gross margin was 48.0% for the second quarter of 2022, compared to 60.2% in the prior-year period. The decline in gross margin compared to the second quarter of 2021 was primarily due to lower fixed overhead absorption, along with a
Selling, general and administrative expenses for the second quarter of 2022 were
Second-quarter research and development expenses were
The net loss for the second quarter of 2022 was
Cash and cash equivalents were approximately
Webcast and Conference Call Information
The Company will host a conference call and webcast at
Investors interested in listening to the conference call may do so by following one of the below links:
- Webcast link for interested listeners:
- Dial-in registration for sell-side research analysts:
An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FINANCIAL STATEMENTS
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) |
||||||||
2022 |
2021 |
|||||||
| ASSETS | (unaudited) | |||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 15,345 | $ | 24,205 | ||||
| Accounts receivable | 1,313 | 750 | ||||||
| Inventories | 3,010 | 2,843 | ||||||
| Other current assets | 252 | 328 | ||||||
| Total current assets | 19,920 | 28,126 | ||||||
| Property, plant and equipment, net | 1,063 | 1,188 | ||||||
| Operating lease right-of-use asset | 994 | 1,082 | ||||||
| Other assets | 21 | 21 | ||||||
| TOTAL ASSETS | $ | 21,998 | $ | 30,417 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,550 | $ | 1,414 | ||||
| Accrued compensation | 1,633 | 1,664 | ||||||
| Current portion of operating lease liability | 186 | 167 | ||||||
| Current portion of finance lease liability | 27 | 26 | ||||||
| Other current liabilities | 63 | 36 | ||||||
| Total current liabilities | 3,459 | 3,307 | ||||||
| Operating lease liability | 860 | 956 | ||||||
| Finance lease liability | 15 | 28 | ||||||
| Other long-term liability | — | 179 | ||||||
| Total liabilities | 4,334 | 4,470 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Series A junior participating preferred stock as of |
— | — | ||||||
| Series F convertible preferred stock as of both |
— | — | ||||||
| Preferred stock as of both |
— | — | ||||||
| Common stock as of |
1 | 1 | ||||||
| Additional paid-in capital | 279,350 | 278,873 | ||||||
| Accumulated other comprehensive income: | ||||||||
| Foreign currency translation adjustment | (12 | ) | (11 | ) | ||||
| Accumulated deficit | (261,675 | ) | (252,916 | ) | ||||
| Total stockholders’ equity | 17,664 | 25,947 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 21,998 | $ | 30,417 | ||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) |
|||||||||||||||||||
| Three months ended |
Six months ended |
||||||||||||||||||
| 2022 |
2021 |
2022 |
2021 |
||||||||||||||||
| Net sales | $ | 2,213 | $ | 2,508 | $ | 4,139 | $ | 4,426 | |||||||||||
| Cost of goods sold | 1,150 | 997 | 1,974 | 1,949 | |||||||||||||||
| Gross profit | 1,063 | 1,511 | 2,165 | 2,477 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Selling, general and administrative | 4,257 | 5,063 | 8,669 | 10,300 | |||||||||||||||
| Research and development | 1,107 | 1,174 | 2,213 | 2,121 | |||||||||||||||
| Total operating expenses | 5,364 | 6,237 | 10,882 | 12,421 | |||||||||||||||
| Loss from operations | (4,301 | ) | (4,726 | ) | (8,717 | ) | (9,944 | ) | |||||||||||
| Other income (expense), net | 17 | (2 | ) | (38 | ) | (3 | ) | ||||||||||||
| Loss before income taxes | (4,284 | ) | (4,728 | ) | (8,755 | ) | (9,947 | ) | |||||||||||
| Income tax expense | (2 | ) | (3 | ) | (4 | ) | (5 | ) | |||||||||||
| Net loss | $ | (4,286 | ) | $ | (4,731 | ) | $ | (8,759 | ) | $ | (9,952 | ) | |||||||
| Basic and diluted loss per share | $ | (0.41 | ) | $ | (0.72 | ) | $ | (0.83 | ) | $ | (2.04 | ) | |||||||
| Weighted average shares outstanding – basic and diluted | 10,538 | 6,532 | 10,538 | 4,887 | |||||||||||||||
| Other comprehensive loss: | |||||||||||||||||||
| Foreign currency translation adjustments | $ | 1 | $ | — | $ | (1 | ) | $ | (3 | ) | |||||||||
| Total comprehensive loss | $ | (4,285 | ) | $ | (4,731 | ) | $ | (8,760 | ) | $ | (9,955 | ) | |||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) |
||||||||
| Six months ended |
||||||||
| 2022 |
2021 |
|||||||
| Operating Activities: | ||||||||
| Net loss | $ | (8,759 | ) | $ | (9,952 | ) | ||
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
| Depreciation and amortization | 206 | 256 | ||||||
| Stock-based compensation expense, net | 477 | 736 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (563 | ) | (272 | ) | ||||
| Inventory | (167 | ) | 122 | |||||
| Other current assets | 76 | (176 | ) | |||||
| Other assets and liabilities | (152 | ) | 9 | |||||
| Accounts payable and accrued expenses | 117 | 75 | ||||||
| Net cash used in operating activities | (8,765 | ) | (9,202 | ) | ||||
| Investing Activities: | ||||||||
| Purchases of property and equipment | (81 | ) | (137 | ) | ||||
| Net cash used in investing activities | (81 | ) | (137 | ) | ||||
| Financing Activities: | ||||||||
| Proceeds from public stock offerings, net | — | 18,896 | ||||||
| Proceeds from warrant exercises | — | 1 | ||||||
| Payments on finance lease liability | (13 | ) | (14 | ) | ||||
| Net cash provided (used in) by financing activities | (13 | ) | 18,883 | |||||
| Effect of exchange rate changes on cash | (1 | ) | (3 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | (8,860 | ) | 9,541 | |||||
| Cash and cash equivalents - beginning of period | 24,205 | 14,437 | ||||||
| Cash and cash equivalents - end of period | $ | 15,345 | $ | 23,978 | ||||
| Supplemental cash flow information | ||||||||
| Inventory transferred to property, plant and equipment | $ | — | $ | 179 | ||||
INVESTOR CONTACTS:
Chief Financial Officer,
ir@nuwellis.com
Matt.Bacso@gilmartinir.com
Source: Nuwellis, Inc.
